Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart stent showdown: which one heals better?

NCT ID NCT04465669

Knowledge-focused Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how two types of drug-coated heart stents (Orsiro and Resolute Integrity) heal inside the arteries of 50 people with stable heart disease. Researchers used a special camera to check the healing 4 months after the stents were placed. The goal was to see if one stent leads to more even tissue coverage than the other.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jan 2020

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years; * Patients with symptoms of stable angina and/or presence of a positive functional test for ischemia; * Patient is eligible for percutaneous coronary intervention (PCI); * Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site. Exclusion Criteria: * Target lesion involving a bifurcation with a side branch ≥2.0 mm in diameter; * Target lesion located in the left main stem; * Target lesion is located or supplied by an arterial or venous bypass graft; * Lesion located very distally, difficult to be imaged by OCT; * Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year; * Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study; * Patient underwent target vessel revascularization with a DES; * Patient presenting with acute myocardial infarction with ST elevation; * Cerebrovascular accident within the past 12 months; * Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl); * Patient receiving oral anticoagulants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina, Stable coronary artery disorder Coronary Disease silent myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary heart disease Silent myocardial ischemia Stable angina pectoris

Contacts and locations

Locations

  • Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

    Tyumen, 625026, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.